The insider sales are immaterial in size and involve only directors, not C-suite. No bearish signal. Monitor for any C-suite selling or larger volume (>0.5% of market cap) in coming weeks, but this cluster alone does not warrant action.
ABEO drugs
ABEO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 26 $5.49entry
- T+1 · 6mo ago +3.64%α +3.63% · $5.69
- T+5 · 6mo ago +3.64%α +2.43% · $5.69
- T+20 · 5mo ago +3.92%α +5.86% · $5.71
- T+60 · 3mo ago +11.66%α +8.93% · $6.13
Price Chart
How similar events traded
Executive Summary
Two directors at Abeona Therapeutics sold a total of $180K in open-market transactions within a week of the company's Q1 2026 earnings report. The sales are small relative to the $315M market cap (0.06%) and are not clustered among C-suite executives, making them routine portfolio adjustments rather than informed selling.
Key Financial Metrics
Key Facts
- Director Mark Alvino sold 6,500 shares at $5.46 for $35K on May 22, 2026
- Director Eric Crombez sold 26,100 shares at $5.53 for $145K on May 15, 2026
- Total insider sales of $180K represent 0.06% of $315M market cap
- Both sellers are directors, not C-suite executives
- Sales occurred 2-9 days after Q1 2026 earnings release (net product revenue $8.7M, net loss -$17.1M)
Financial Impact
Insider sales of $180K, or 0.06% of market cap, trivial
Risk Factors
- No material risk from this cluster, sales are routine and small
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ABEO-1779485088592 |
Track record
29 reports on ABEO
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +15.24% at T+20 after the Sep 29, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $2.30 Now $2.60 +13.04% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $2.29 to $2.42 Now $2.60 +13.54% ▲ +5.68% +6.04% vs SPY
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $2.54 to $2.46 Now $2.60 −2.36% ▲ +3.35% +2.98% vs SPY
- Nov 9, 20267d ago Press Release Mixed 6/10 Entry $2.54 to $2.46 Now $2.60 +2.36% ▼ −3.35% −2.98% vs SPY
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $4.17 to $2.54 Now $2.60 −37.65% ▼ −39.09% −41.46% vs SPY
- Oct 23, 202624d ago SC 13D Bullish 6/10 Entry $4.40 to $4.31 Now $2.60 −40.91% ▼ −2.05% −2.76% vs SPY
- Sep 29, 20266w ago Insider Cluster Bearish 4/10 Entry $5.25 to $5.01 Now $2.60 +50.48% ▲ +4.57% +4.75% vs SPY
- Sep 18, 20268w ago Press Release Bullish 6/10 Entry $5.57 to $5.67 Now $2.60 −53.32% ▲ +1.80% +0.24% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers